ArticleBMC musculoskeletal disorders2025
Body composition, bone mineral density, and functional impairment in axial spondyloarthritis: a 36-month longitudinal study.
Article in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Disease-modifying anti-rheumatic drugs and systemic glucocorticoid use and risk of vertebral fractures in axial spondyloarthropathies: a systematic review and meta-analysis.Clinical rheumatology · 2026Pooled it
- Disentangling the association between chronic pain and sarcopenia-related traits: A bidirectional Mendelian randomization study.The Journal of international medical research · 2026Article
- Associations of muscle mass, adipose tissue mass, and skeletal muscle radiodensity with disease activity in axial spondyloarthritis.Therapeutic advances in musculoskeletal disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAxial spondyloarthritis (ax-SpA) is a chronic inflammatory disease affecting the axial skeleton, peripheral joints, And entheses, often leading to pain, stiffness, And extra-articular complications. Its impact on muscle and bone health has gained attention, as chronic inflammation, reduced physical activity, sedentary behaviour, and glucocorticoid therapy, may alter body composition, particularly lean mass and adipose tissue distribution. This study explores the association between disease activity, body composition, and bone parameters in ax-SpA patients over a 36-month period.
methodsThis longitudinal study was conducted at Padua University Hospital (Italy). The following data was collected at baseline And 36 months: medical history, phospho-calcium metabolism, anthropometric measurements, handgrip strength (using hand dynamometer), sit-to-stand test, and Dual-Energy X-ray Absorptiometry assessments. Patients completed Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and Health Assessment Questionnaire (HAQ). Correlations between questionnaire scores and clinical variables were analysed, and changes from baseline to follow-up were assessed using paired comparisons.
resultsTwenty participants (10 ax-SpA, 10 matched controls) were enrolled. At baseline, no significant differences in bone and body composition were found between groups. In ax-SpA patients, BASFI correlated with BMI (r = 0.800, p < 0.01), fat percentage (r = 0.808, p < 0.01), and fat mass index (r = 0.903, p < 0.01), while BASDAI correlated with sit-to-stand performance (r = 0.677, p < 0.05) and fat percentage (r = 0.700, p < 0.05). After 36 months, significant improvements were observed in sit-to-stand scores [from 17.37 (7.47) to 11.98 (3.81), p = 0.02] and femoral neck BMD [from 0.89 (0.13) to 1.02 (0.14), p = 0.01]. Sit-to-stand improvements correlated with BASFI (r = 0.78, p < 0.01), and ASMMI changes correlated with HAQ (r = 0.92, p < 0.001).
conclusionOur findings suggest that greater muscle mass and physical performance are associated with lower disease activity and improved quality of life in ax-SpA patients. These associations support integrating pharmacologic treatment with structured exercise, although causal inferences cannot be drawn from this observational design. Further studies are needed to clarify the directionality and underlying mechanisms.
trial registrationNot applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.